Advertisement

Local Treatments and Supportive Care

  • Salma Faghri de la FeldEmail author
  • Naveed Sami
Chapter

Abstract

While the primary treatment of autoimmune blistering diseases (ABD) has been systemic therapy, it is important to be aware of the value of several non-systemic treatments. Topical corticosteroids (both as monotherapy and adjuvant therapy), intra-lesional corticosteroids and corticosteroid elixirs can play an important role in treatment. In addition, non-steroidal treatments such as topical calcineurin inhibitors and non-steroidal elixirs have also been reported in treatment of ABD. Furthermore, it is important to be aware of exogenous factors contributing to ABD (including food and nutrition, iodine, poor oral hygiene and ultraviolet light). Treatment of ABD is not complete without consideration of infection control and vaccination guidelines. Systemic antihistamines are also helpful in controlling symptoms of pruritus. A variety of local treatment options have proven to be beneficial in mild as well as moderate and severe disease as an adjuvant. Patients should be constantly encouraged and reminded that these measures may help reduce the dosage and duration of their systemic treatments, and in some mild cases provide remission of the ABD.

Keywords

Local treatments in autoimmune blistering diseases Adjuvant treatments in autoimmune blistering diseases Topical corticosteroids Intralesional corticosteroids Side effects of local corticosteroids Non-steroidal topical therapies Elixirs Infection control Vaccines Ultraviolet light Food and nutrition Antihistamines 

References

  1. 1.
    Person JR, Rogers RS, Perry HO. Localized pemphigoid. Br J Dermatol. 1976;95(5):531–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Taghipour K, Mohd Mustapa MF, Highet AS, Venning VA, Kirtschig G. The approach of dermatologists in the UK to the treatment of bullous pemphigoid: results of a national survey. Clin Exp Dermatol. 2013;38(3):311–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20(3):458–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Joly P, Roujeau J-C, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Gelfand JM, Werth VP. Treatment of bullous pemphigoid with topical corticosteroids: review of a randomized controlled trial. Arch Dermatol. 2002;138(9):1236–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Korman NJ. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med. 2002;347(2):143–5; author reply 143–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Spigel GT. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med. 2002;347(2):143–5; author reply 143–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Joly P, Roujeau J-C, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Stockman A, Beele H, Vanderhaeghen Y, Naeyaert JM. Topical class I corticosteroids in 10 patients with bullous pemphigoid: correlation of the outcome with the severity degree of the disease and review of the literature. J Eur Acad Dermatol Venereol JEADV. 2004;18(2):164–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Terra JB, Potze WJB, Jonkman MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. J Eur Acad Dermatol Venereol JEADV. 2014;28(6):712–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Claudy A. Evaluation of the safety and efficacy of a potent topical cortico-steroid in the treatment of bullous pemphigoid. Clin Dermatol. 2001;19(6):778–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Zimmermann R, Faure M, Claudy A. Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid. Ann Dermatol Venereol. 1999;126(1):13–6.PubMedGoogle Scholar
  13. 13.
    Paquet P, Richelle M, Lapiere CM. Bullous pemphigoid treated by topical corticosteroids. Acta Derm Venereol. 1991;71(6):534–5.PubMedGoogle Scholar
  14. 14.
    Muramatsu T, Iida T, Shirai T. Pemphigoid and pemphigus foliaceus successfully treated with topical corticosteroids. J Dermatol. 1996;23(10):683–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Bingham LG, Noble JW, Davis MDP. Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study. J Am Acad Dermatol. 2009;60(5):792–800.PubMedCrossRefGoogle Scholar
  16. 16.
    Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Dumas V, Roujeau JC, Wolkenstein P, Revuz J, Cosnes A. The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid. Br J Dermatol. 1999;140(6):1127–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Du-Thanh A, Merlet S, Maillard H, Bernard P, Joly P, Estève E, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Mervic L, Dragos V, Pavlović MD. Linear IgA bullous dermatosis of childhood: successful treatment with miocamycin and topical corticosteroid. Clin Exp Dermatol. 2009;34(7):e391–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Hornschuh B, Hamm H, Wever S, Hashimoto T, Schröder U, Bröcker EB, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol. 1997;36(1):101–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Lozada F, Silverman S. Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol. 1980;116(8):898–901.PubMedCrossRefGoogle Scholar
  22. 22.
    Aufdemorte TB, De Villez RL, Parel SM. Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol. 1985;59(3):256–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05 % clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05 % fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77(6):598–604.PubMedCrossRefGoogle Scholar
  24. 24.
    Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2008;37(6):341–4.Google Scholar
  25. 25.
    Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, Morales-Garcia P, Mesa-Aguado F, Bascones-Martinez A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(6):688–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Ahmed AR, Rogers RS. Bullous pemphigoid. Therapy and management. Clin Dermatol. 1987;5(1):146–54.PubMedCrossRefGoogle Scholar
  27. 27.
    Hempstead RW, Marks JG. Pediatric pemphigus vulgaris. Treatment with topical adrenal steroids. Arch Dermatol. 1984;120(7):962–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Ahmed AR, Kurgis BS, Rogers RS. Cicatricial pemphigoid. J Am Acad Dermatol. 1991;24(6 Pt 1):987–1001.PubMedCrossRefGoogle Scholar
  29. 29.
    Mignogna MD, Fortuna G, Leuci S, Adamo D, Dell’Aversana Orabona G, Ruoppo E. Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris. J Eur Acad Dermatol Venereol JEADV. 2010;24(10):1157–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Moura EG, Couto-Júnior DS, Alvarado-Escobar H, da Costa-Martins B, Sallum RA, Artifon EL, et al. Epidermolysis bullosa acquisita complicated by esophageal stenosis. Endoscopic treatment with thermoplastic dilators and intralesional steroid injection. Rev Gastroenterol Méx. 2011;76(3):279–85.PubMedGoogle Scholar
  31. 31.
    Singh AP, Chaitra TR, Ravishankar TL, Singh SP, Mohapatra AK. HIV patient with mucous membrane pemphigoid: a case report. Ethiop J Health Sci. 2014;24(2):179–82.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Fortuna G, Mignogna MD. Clinical guidelines for the use of adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris: the oral medicine point of view. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2011;40(4):359–60.Google Scholar
  33. 33.
    Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IR-A, Gonzalez-Moles S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(3):264–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38(2 Pt 2):318–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993;29(3):501–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol. 1988;90(4):532–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol. 2003;139(6):813–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Chuh AA. The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol. 2004;150(3):622–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Ko M-J, Chu C-Y. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol. 2003;149(5):1079–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Calcaterra R, Carducci M, Franco G, Mussi A, Morrone A. Topical tacrolimus treatment for localized pretibial bullous phemphigoid. J Eur Acad Dermatol Venereol JEADV. 2009;23(2):177–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Günther C, Wozel G, Meurer M, Pfeiffer C. Topical tacrolimus treatment for cicatricial pemphigoid. J Am Acad Dermatol. 2004;50(2):325–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol. 2004;29(6):674–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist Off Publ Am Assoc Hosp Dent Acad Dent Handicap Am Soc Geriatr Dent. 2006;26(2):66–70.Google Scholar
  44. 44.
    Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol. 2011;91(5):604–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Hall VC, Liesegang TJ, Kostick DA, Lookingbill DP. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol. 2003;139(8):1083–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Cohen SN, Lim RPR, Paul CJ, Abdullah A. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol. 2006;45(11):1379.PubMedCrossRefGoogle Scholar
  47. 47.
    Iraji F, Asilian A, Siadat AH. Pimecrolimus 1 % cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol JDD. 2010;9(6):684–6.PubMedGoogle Scholar
  48. 48.
    Hull CM, McKenna JK, Zone JJ. Topical corticosteroids and bullous pemphigoid. Arch Dermatol. 2003;139(2):225–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Dauendorffer JN, Mahé E, Saiag P. Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. J Eur Acad Dermatol Venereol JEADV. 2008;22(3):364–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Bauco van der Wal V, Jonkman MF. Topical tetracycline in cicatricial pemphigoid. J Am Acad Dermatol. 1997;36(3 Pt 1):492–3.PubMedCrossRefGoogle Scholar
  51. 51.
    Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207–14.PubMedCrossRefGoogle Scholar
  52. 52.
    Poot AM, Jonkman MF. Topical sirolimus for oral pemphigus vulgaris: 3 unresponsive cases. J Am Acad Dermatol. 2012;67(5):e228–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Eisen D, Ellis CN, Voorhees JJ. Topical cyclosporine for oral bullous disorders. J Am Acad Dermatol. 1990;23(5 Pt 1):936–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Gooptu C, Staughton RC. Use of topical cyclosporin in oral pemphigus. J Am Acad Dermatol. 1998;38(5 Pt 2):860–1.PubMedCrossRefGoogle Scholar
  55. 55.
    Brenner S, Srebrnik A, Goldberg I. Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols. J Cosmet Dermatol. 2003;2(3–4):161–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Goldberg I, Kashman Y, Brenner S. The induction of pemphigus by phenol drugs. Int J Dermatol. 1999;38(12):888–92.PubMedCrossRefGoogle Scholar
  57. 57.
    Brenner S, Tur E, Shapiro J, Ruocco V, D’Avino M, Ruocco E, et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol. 2001;40(9):562–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Brenner S, Wolf R, Ruocco V. Contact pemphigus: a subgroup of induced pemphigus. Int J Dermatol. 1994;33(12):843–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Fawzy MM, Hegazy RA, Abdel Fattah AF. Ear, nose, and throat involvement in Egyptian patients with pemphigus vulgaris: a step towards a better management. Int J Dermatol. 2013;52(10):1268–73.PubMedGoogle Scholar
  60. 60.
    Valikhani M, Kavusi S, Chams-Davatchi C, Hallaji Z, Esmaili N, Ghandi N, et al. Impact of smoking on pemphigus. Int J Dermatol. 2008;47(6):567–70.PubMedCrossRefGoogle Scholar
  61. 61.
    Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31(4):382–90.PubMedCrossRefGoogle Scholar
  62. 62.
    Tur E, Brenner S. Contributing exogenous factors in pemphigus. Int J Dermatol. 1997;36(12):888–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Wohl Y, Brenner S. Pemphigus in Israel--an epidemiologic analysis of cases in search of risk factors. Isr Med Assoc J IMAJ. 2003;5(6):410–2.PubMedGoogle Scholar
  64. 64.
    Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138(7):903–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Hervonen K, Salmi TT, Ilus T, Paasikivi K, Vornanen M, Laurila K, et al. Dermatitis herpetiformis refractory to gluten-free dietary treatment. Acta Derm Venereol. 2016;96(1):82–86.Google Scholar
  66. 66.
    Lewis HM, Renaula TL, Garioch JJ, Leonard JN, Fry JS, Collin P, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol. 1996;135(3):363–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Gainer CL. Celiac disease: helping patients live gluten-free. Nurse Pract. 2011;36(9):14–9; quiz 19–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Thompson T, Simpson S. A comparison of gluten levels in labeled gluten-free and certified gluten-free foods sold in the United States. Eur J Clin Nutr. 2015;69(2):143–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Collin P, Thorell L, Kaukinen K, Mäki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther. 2004;19(12):1277–83.PubMedCrossRefGoogle Scholar
  70. 70.
    Mulder CJJ, van Wanrooij RLJ, Bakker SF, Wierdsma N, Bouma G. Gluten-free diet in gluten-related disorders. Dig Dis. 2013;31(1):57–62.PubMedCrossRefGoogle Scholar
  71. 71.
    Penagini F, Dilillo D, Meneghin F, Mameli C, Fabiano V, Zuccotti GV. Gluten-free diet in children: an approach to a nutritionally adequate and balanced diet. Nutrients. 2013;5(11):4553–65.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    From E, Thomsen K. Dermatitis herpetiformis. A case provoked by iodine. Br J Dermatol. 1974;91(2):221–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Sciallis GF. Letter: dermatitis herpetiformis and iodine. Br J Dermatol. 1976;94(3):343.PubMedCrossRefGoogle Scholar
  74. 74.
    Douglas WS, Alexander JO. Letter: dermatitis herpetiformis, iodine compounds and thyrotoxicosis. Br J Dermatol. 1975;92(5):596–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Arduino PG, Farci V, D’Aiuto F, Carcieri P, Carbone M, Tanteri C, et al. Periodontal status in oral mucous membrane pemphigoid: initial results of a case-control study. Oral Dis. 2011;17(1):90–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Tricamo MB, Rees TD, Hallmon WW, Wright JM, Cueva MA, Plemons JM. Periodontal status in patients with gingival mucous membrane pemphigoid. J Periodontol. 2006;77(3):398–405.PubMedCrossRefGoogle Scholar
  77. 77.
    Schellinck AE, Rees TD, Plemons JM, Kessler HP, Rivera-Hidalgo F, Solomon ES. A comparison of the periodontal status in patients with mucous membrane pemphigoid: a 5-year follow-up. J Periodontol. 2009;80(11):1765–73.PubMedCrossRefGoogle Scholar
  78. 78.
    Arduino PG, Lopetuso E, Carcieri P, Giacometti S, Carbone M, Tanteri C, et al. Professional oral hygiene treatment and detailed oral hygiene instructions in patients affected by mucous membrane pemphigoid with specific gingival localization: a pilot study in 12 patients. Int J Dent Hyg. 2012;10(2):138–41.PubMedCrossRefGoogle Scholar
  79. 79.
    Cram DL, Winkelmann RK. Ultraviolet-induced acantholysis in pemphigus. Arch Dermatol. 1965;92(1):7–13.PubMedCrossRefGoogle Scholar
  80. 80.
    Igawa K, Matsunaga T, Nishioka K. Involvement of UV-irradiation in pemphigus foliaceus. J Eur Acad Dermatol Venereol JEADV. 2004;18(2):216–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Reis VM, Toledo RP, Lopez A, Diaz LA, Martins JE. UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol. 2000;42(4):571–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Rodan KP, Fleischmann H, Nickoloff BJ, Egbert B. Generalized blistering eruption aggravated by heat. Pemphigus foliaceus. Arch Dermatol. 1987;123(3):394, 397–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Cram DL, Fukuyama K. Immunohistochemistry of ultraviolet-induced pemphigus and pemphigoid lesions. Arch Dermatol. 1972;106(6):819–24.PubMedCrossRefGoogle Scholar
  84. 84.
    Lee CW, Ro YS. Sun-induced localized bullous pemphigoid. Br J Dermatol. 1992;126(1):91–2.PubMedCrossRefGoogle Scholar
  85. 85.
    Thomsen K, Schmidt H. PUVA-induced bullous pemphigoid. Br J Dermatol. 1976;95(5):568–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Jacobs SE. Pemphigus Erythematosus and ultraviolet light. A case report. Arch Dermatol. 1965;91:139–41.PubMedCrossRefGoogle Scholar
  87. 87.
    Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity. Br J Dermatol. 2000;142(3):517–20.PubMedCrossRefGoogle Scholar
  88. 88.
    Salmhofer W, Soyer HP, Wolf P, Födinger D, Hödl S, Kerl H. UV light-induced linear IgA dermatosis. J Am Acad Dermatol. 2004;50(1):109–15.PubMedCrossRefGoogle Scholar
  89. 89.
    Rakvit P, Kerr AC, Ibbotson SH. Localized bullous pemphigoid induced by photodynamic therapy. Photodermatol Photoimmunol Photomed. 2011;27(5):251–3.PubMedCrossRefGoogle Scholar
  90. 90.
    Cafaro A, Broccoletti R, Arduino PG. Low-level laser therapy for oral mucous membrane pemphigoid. Lasers Med Sci. 2012;27(6):1247–50.PubMedCrossRefGoogle Scholar
  91. 91.
    Yilmaz HG, Kusakci-Seker B, Bayindir H, Tözüm TF. Low-level laser therapy in the treatment of mucous membrane pemphigoid: a promising procedure. J Periodontol. 2010;81(8):1226–30.PubMedCrossRefGoogle Scholar
  92. 92.
    Oliveira PC, Reis Junior JA, Lacerda JA, Silveira NT, Santos JM, Vitale MC, et al. Laser light may improve the symptoms of oral lesions of cicatricial pemphigoid: a case report. Photomed Laser Surg. 2009;27(5):825–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN. Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin. 2011;29(4):591–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Leshem YA, Gdalevich M, Ziv M, David M, Hodak E, Mimouni D. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol. 2014;71(2):284–92.PubMedCrossRefGoogle Scholar
  95. 95.
    Boughrara Z, Ingen-Housz-Oro S, Legrand P, Duong T-A, Roujeau J-C. Cutaneous infections in bullous pemphigoid patients treated with topical corticosteroids. Ann Dermatol Vénéréol. 2010;137(5):345–51.PubMedCrossRefGoogle Scholar
  96. 96.
    Carducci M, Nosotti L, Calcaterra R, Bonifati C, Mussi A, Pelagalli L, et al. Early development of disseminated nocardiosis during immunosuppressive treatment for pemphigus vulgaris. Eur J Dermatol EJD. 2007;17(4):346–7.PubMedGoogle Scholar
  97. 97.
    Asilian A, Yoosefi A, Faghihi G. Cutaneous and pulmonary nocardiosis in pemphigus vulgaris: a rare complication of immunosuppressive therapy. Int J Dermatol. 2006;45(10):1204–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Kakurai M, Hiraga T, Yamada T, Usui K, Kiyosawa T, Nakagawa H. Subcutaneous nocardial abscesses in a patient with bullous pemphigoid during immunosuppressive therapy: report of a case and review of the Japanese literature. J Dermatol. 1999;26(12):829–33.PubMedCrossRefGoogle Scholar
  99. 99.
    Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7(2):221–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Barrick BJ, Lohse CM, Lehman JS. Specific causes of death in patients with bullous pemphigoid as measured by death certificate data: a retrospective cohort study. Int J Dermatol. 2015;54(1):56–61.PubMedCentralPubMedCrossRefGoogle Scholar
  101. 101.
    Gerhart JL, Kalaaji AN. Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications. J Am Acad Dermatol. 2010;62(6):957–61.PubMedCrossRefGoogle Scholar
  102. 102.
    Li F, Jin H-Z, Su F, Jia L, Sun Q-N. Pneumocystis pneumonia in patients with immunobullous dermatoses. Int J Dermatol. 2011;50(9):1144–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J Am Acad Dermatol. 2010;63(5):815–23.PubMedCrossRefGoogle Scholar
  104. 104.
    Grattan CE, Small D, Kennedy CT, Scully C. Oral herpes simplex infection in bullous pemphigoid. Oral Surg Oral Med Oral Pathol. 1986;61(1):40–3.PubMedCrossRefGoogle Scholar
  105. 105.
    Kalajian AH, Callen JP. A typical herpes simplex infection masquerading as recalcitrant pemphigus vulgaris. Australas J Dermatol. 2007;48(4):242–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Negosanti M, Cevenini R, Ghetti P, Fanti PA, Gasponi A, Tosti A. Severe herpetic gingivostomatitis associated with pemphigus vulgaris. Arch Dermatol. 1984;120(4):540–2.PubMedCrossRefGoogle Scholar
  107. 107.
    Niederecker C, Tappeiner G, Wolff K. Generalized herpes simplex infection complicating bullous pemphigoid. Br J Dermatol. 1995;132(3):484–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Cliff S, Ostlere LS, Harland CC. Varicella zoster virus infection complicating bullous pemphigoid. Clin Exp Dermatol. 1996;21(2):174–5.CrossRefGoogle Scholar
  109. 109.
    Orenstein JM, Castadot MJ, Wilens SL. Fatal herpes hepatitis associated with pemphigus vulgaris and steroids in an adult. Hum Pathol. 1974;5(4):489–93.PubMedCrossRefGoogle Scholar
  110. 110.
    Keane JT, Malkinson FD, Bryant J, Levin S. Herpesvirus hominis hepatitis and disseminated intravascular coagulation. Occurrence in an adult with pemphigus vulgaris. Arch Intern Med. 1976;136(11):1312–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Nikkels AF, Delvenne P, Herfs M, Pierard GE. Occult herpes simplex virus colonization of bullous dermatitides. Am J Clin Dermatol. 2008;9(3):163–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Svecova D, Chmurova N, Pallova A, Babal P. Norwegian scabies in immunosuppressed patient misdiagnosed as an adverse drug reaction. Epidemiol Mikrobiol Imunol Cas Spolecnosti Epidemiol Mikrobiol Ceské Lékarské Spolecnosti JE Purkyne. 2009;58(3):121–3.Google Scholar
  113. 113.
    Roxana Stan T, Piaserico S, Bordignon M, Salmaso R, Zattra E, Alaibac M. Bullous scabies simulating pemphigoid. J Cutan Med Surg. 2011;15(1):55–7.PubMedCrossRefGoogle Scholar
  114. 114.
    Ansarin H, Jalali MHA, Mazloomi S, Soltani-Arabshahi R, Setarehshenas R. Scabies presenting with bullous pemphigoid-like lesions. Dermatol Online J. 2006;12(1):19.PubMedGoogle Scholar
  115. 115.
    Brar BK, Pall A, Gupta RR. Bullous scabies mimicking bullous pemphigoid. J Dermatol. 2003;30(9):694–6.PubMedCrossRefGoogle Scholar
  116. 116.
    Balighi K, Robati RM, Hejazi N. A dilemma: bullous-pemphigoid-like eruption in scabies or scabies-induced bullous pemphigoid. Dermatol Online J. 2006;12(4):13.PubMedGoogle Scholar
  117. 117.
    Hylwa SA, Loss L, Grassi M. Crusted scabies and tinea corporis after treatment of presumed bullous pemphigoid. Cutis. 2013;92(4):193–8.PubMedGoogle Scholar
  118. 118.
    Hsiao GH, Chiu HC. Dermatophyte infection associated with a local recurrence of bullous pemphigoid. Br J Dermatol. 1995;132(5):833–5.PubMedCrossRefGoogle Scholar
  119. 119.
    Sugiura K, Sugiura N, Yagi T, Iguchi M, Ohno H, Miyazaki Y, et al. Cryptococcal cellulitis in a patient with bullous pemphigoid. Acta Derm Venereol. 2013;93(2):187–8.PubMedCrossRefGoogle Scholar
  120. 120.
    Yen A, Knipe RC, Tyring SK. Primary cutaneous blastomycosis: report of a case acquired by direct inoculation of a bullous pemphigoid lesion. J Am Acad Dermatol. 1994;31(2 Pt 1):277–8.PubMedCrossRefGoogle Scholar
  121. 121.
    Martín FJ, Pérez-Bernal AM, Camacho F. Pemphigus vulgaris and disseminated nocardiosis. J Eur Acad Dermatol Venereol JEADV. 2000;14(5):416–8.PubMedCrossRefGoogle Scholar
  122. 122.
    CDC – Vaccines – Adult immunization schedules and tools for providers [Internet]. [cited 2015 Jun 30]. Available from: http://www.cdc.gov/vaccines/schedules/hcp/adult.html.
  123. 123.
    Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother. 2012;3(2):105–8.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyEmory University School of MedicineAtlantaUSA
  2. 2.Department of DermatologyUniversity of Alabama – BirminghamBirminghamUSA

Personalised recommendations